Sensitivity, specificity, positive predictive value and negative predictive value of antibody isotypes when comparing patients with anti-CCP-positive RA versus non-RA patients (persistent non-RA and resolving)
| Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | |
|---|---|---|---|---|
| Anti-CCP | 100% (92.5% to 100%) | 98.2% (94.8% to 99.6%) | 94.1% (83.7% to 98.7%) | 100% (97.8% to 100%) |
| Rheum factor | ||||
| IgG | 93.8% (82.8% to 98.6%) | 92.2% (87.1% to 95.8%) | 77.6% (64.7% to 87.5%) | 98.1% (94.5% to 99.6%) |
| IgA | 56.3% (41.2% to 70.5%) | 91.0% (85.6% to 94.9%) | 64.3% (48.0% to 78.4%) | 87.9% (82.0% to 92.3%) |
| Anti-CitVimentin | ||||
| IgG | 93.8% (82.8% to 98.6%) | 83.3% (76.7% to 88.6%) | 61.6% (49.5% to 72.8%) | 97.9% (93.9% to 99.5%) |
| IgA | 62.5% (47.5% to 76.0%) | 73.2% (65.6% to 79.6%) | 40.0% (28.9% to 51.9%) | 87.1% (80.4% to 92.2%) |
| Anti-CarVimentin | ||||
| IgG | 68.8% (53.8% to 81.3%) | 94.0% (89.3% to 97.1%) | 76.7% (61.4% to 88.2%) | 91.3% (86.0% to 95.0%) |
| IgA | 16.7% (7.5% to 30.2%) | 88.0% (82.1% to 92.5% | 28.6% (13.3% to 48.7%) | 78.6% (72.0% to 84.3%) |
| Anti-AcVimentin | ||||
| IgG | 62.5% (47.5% to 76.0%) | 86.2% (80.1% to 91.1%) | 56.6% (42.3% to 70.2%) | 88.9% (83.0% to 93.3%) |
| IgA | 41.7% (27.6% to 56.8% | 64.7% (56.9% to 71.9%) | 25.3% (16.2% to 36.4%) | 79.4% (71.6% to 85.9%) |
AcVim, acetylated vimentin peptide; CarVim, carbamylated vimentin peptide; CitVim, citrullinated vimentin peptide; NPV, negative predictive value; PPV, positive predictive value; RA, rheumatoid arthritis.